OrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesHealth CareGeographicals
Diphtheria ToxoidDiphtheriaDiphtheria ToxinTetanus ToxoidDiphtheria AntitoxinToxoidsDiphtheria-Tetanus VaccineDiphtheria-Tetanus-acellular Pertussis VaccinesTetanusCorynebacterium diphtheriaeDiphtheria-Tetanus-Pertussis VaccineWhooping CoughVaccines, CombinedImmunization, SecondaryImmunization ScheduleCommonwealth of Independent StatesVaccines, ConjugateTetanus AntitoxinAntibodies, BacterialVaccinationPertussis VaccineImmunizationAlum CompoundsHaemophilus VaccinesBacterial VaccinesTransfer FactorMeningococcal VaccinesVaccinesImmunoglobulin GAntibody FormationPolysaccharides, BacterialStaphylococcal ToxoidPoliovirus Vaccine, InactivatedUnited States
VaccineVaccinesConjugateImmunizationVaccinationAntitoxinTdapSusceptibility to diphtheriaDose of tetanusToxinAntigensImmunogenicityHepatitis B Surface AntigenAntibodyOutbreaksSerumImmunityAnaphylaxisVaccinationsAdultsCommonlySearchAcellular pertussisVaccinesInduce at least 2 unitsConjugate vaccinePoliovirus vaccineDosesImmunisationStatus against diphtheriaPertussis antigensPoliomyelitisDiseasesAdolescents and adultsStandardizationWhooping coughVaccination coveragePreparationToxinsInfectionVaxelisBacteriaDecreasesLead to difficultyHypersensitivity reactionBoosterInfectiousPrevent2023TDVAXSevereAdditional doseEffectivenessAluminum
Vaccine24
  • On October 27, 2010, ACIP approved the following additional recommendations: 1) use of Tdap regardless of interval since the last tetanus- or diphtheria-toxoid containing vaccine, 2) use of Tdap in certain adults aged 65 years and older, and 3) use of Tdap in undervaccinated children aged 7 through 10 years. (cdc.gov)
  • Since 2005, a single dose of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine has been recommended by the Advisory Committee on Immunization Practices (ACIP) for adolescents and adults (1,2). (nih.gov)
  • After receipt of Tdap, booster doses of tetanus and diphtheria toxoids (Td) vaccine are recommended every 10 years or when indicated for wound management. (nih.gov)
  • Safety and immunogenicity of a single intramuscular dose of a tetanus- diphtheria toxoid (Td) vaccine (BR-TD-1001) in healthy Korean adult subjects. (druglib.com)
  • Medicine Central , im.unboundmedicine.com/medicine/view/Davis-Drug-Guide/51881/all/meningococcal_polysaccharide_diphtheria_toxoid_conjugate_vaccine. (unboundmedicine.com)
  • Vallerand AHA, Sanoski CAC, Quiring CC. Meningococcal polysaccharide diphtheria toxoid conjugate vaccine. (unboundmedicine.com)
  • In 2017, aligned with global World Health Organization tetanus guidelines, Vietnam prepared evidence to support a recommendation to introduce the tetanus - diphtheria (Td) vaccine into routine immunization . (bvsalud.org)
  • This study aimed to provide evidence on the costs and budgetary impact of the potential replacement of the tetanus - toxoid (TT) vaccine with the Td vaccine , considering different possible delivery strategies . (bvsalud.org)
  • To examine the impact of a minimum interval schedule for administering diphtheria and tetanus toxoids and acellular pertussis vaccine (DTaP) in infants during a statewide pertussis outbreak on receipt of inactivated polio vaccine (IPV) and pneumococcal conjugate vaccine (PCV). (qxmd.com)
  • This combined vaccine is indicated for primary and booster vaccination of children against diphtheria, tetanus, pertussis, hepatitis B caused by all known subtypes of viruses, poliomyelitis and invasive infections caused by Haemophilus influenzae type b. (europa.eu)
  • Tdap vaccine can prevent tetanus, diphtheria, and pertussis. (medlineplus.gov)
  • Also, adults should receive a booster dose of either Tdap or Td (a different vaccine that protects against tetanus and diphtheria but not pertussis) every 10 years, or after 5 years in the case of a severe or dirty wound or burn. (medlineplus.gov)
  • Vaccine errors threaten to undermine the protection immunizations provide and often leave patients inadequately protected against serious diseases such as hepatitis A and B, pertussis, diphtheria, cervical cancer, and many others. (ismp.org)
  • BOOSTRIX is a vaccine indicated for active booster immunization against tetanus, diphtheria, and pertussis in individuals aged 10 years and older. (nih.gov)
  • BOOSTRIX may be administered as an additional dose 9 years or more after the initial dose of Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Tdap). (nih.gov)
  • For management of a tetanus-prone wound, a dose of BOOSTRIX may be administered if at least 5 years have elapsed since previous receipt of a tetanus toxoid-containing vaccine. (nih.gov)
  • Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine or to any component of BOOSTRIX. (nih.gov)
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk of Guillain-Barré syndrome may be increased following a subsequent dose of tetanus toxoid-containing vaccine, including BOOSTRIX. (nih.gov)
  • Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine should not receive BOOSTRIX unless at least 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine. (nih.gov)
  • The TDap vaccine is a safe and effective vaccine that provides protection against tetanus (T), diphtheria (D), and acellular pertussis (aP), more commonly known as whooping cough . (familyeducation.com)
  • The DTap vaccine is given to infants to provide initial immunity against tetanus, diphtheria, and pertussis, whereas the TDap vaccine is a booster that became available in 2005 for adults and children over seven. (familyeducation.com)
  • In the United States, the Advisory Committee on Immunization Practices (ACIP) recommends that children aged 11-12 years receive tetanus, diphtheria, and acellular pertussis vaccine (Tdap), meningococcal conjugate vaccine (MenACWY), and human papillomavirus (HPV) vaccine (HPV vaccine can be started at age 9 years). (medscape.com)
  • Tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine coverage represents coverage with ≥1 Tdap dose at age ≥10 years. (medscape.com)
  • Immunization is coded 3E0134Z Introduction of Serum, Toxoid and Vaccine into Subcutaneous Tissue, Percutaneous Approach. (fortherecordmag.com)
Vaccines10
Conjugate1
Immunization4
Vaccination4
Antitoxin3
Tdap1
Susceptibility to diphtheria1
  • Although clinical disease remains rare, the susceptibility to diphtheria observed in these serosurveys highlights the importance of strengthened surveillance. (cambridge.org)
Dose of tetanus1
Toxin19
  • The aim of the research was to compare in vitro characteristics of reception of the natural diphtheria toxin - DT and its nontoxic recombinant analogs - toxoids. (kiev.ua)
  • For assessing ligand-receptor interaction the method of immunoenzyme analysis and ELISA was used, where the bonding layer recombinant analogues of diphtheria toxin cell receptor HB-EGF from sensitive and resistant to the toxin of the organisms were served. (kiev.ua)
  • According to the results of ELISA the natural diphtheria toxin, in contrast to recombinant toxoids - CRM197, and B subunit, interacted with mouse HB-EGF with a very low affinity. (kiev.ua)
  • While human HB-EGF with an equally high affinity connected as toxoids as native diphtheria toxin. (kiev.ua)
  • 1. Collier R. J. Diphtheria toxin: mode of action and structure. (kiev.ua)
  • 2. Naglich J. G., Metherall J. E., Russell D. W., Eidels L. Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. (kiev.ua)
  • 6. Cha J. H., Brooke J. S., Eidels L. Toxin binding site of the diphtheria toxin receptor: loss and gain of diphtheria toxin binding of monkey and mouse heparin-binding, epidermal growth factor-like growth factor precursors by reciprocal site-directed mutagenesis. (kiev.ua)
  • 7. Morris R. E., Saelinger C. B. Diphtheria toxin does not enter resistant cells by receptor-mediated endocytosis. (kiev.ua)
  • 8. Mitamura T., Higashiyama S., Taniguchi N., Klagsbrun M., Mekada E. Diphtheria toxin binds to the epidermal growth factor (EGF)-like domain of human heparin-binding EGF-like growth factor/diphtheria toxin receptor and inhibits specifically its mitogenic activity. (kiev.ua)
  • 9. Mitamura T., Umata T., Nakano F., Shishido Y., Toyoda T., Itai A., Kimura H., Mekada E. Structure-function analysis of the diphtheria toxin receptor toxin binding site by site-directed mutagenesis. (kiev.ua)
  • 10. Moehring T. J., Moehring J. M . Interaction of diphtheria toxin and its active subunit, fragment A, with toxin-sensitive and toxin-resistant cells. (kiev.ua)
  • 11. El Hage T., Decottignies P., Authier F . Endosomal proteolysis of diphtheria toxin without toxin translocation into the cytosol of rat liver in vivo. (kiev.ua)
  • 12. Heagy W. E., Neville D. M. J . Kinetics of protein synthesis inactivation by diphtheria toxin in toxin-resistant L cells. (kiev.ua)
  • 13. Didsbury J. R., Moehring J. M., Moehring T. J. Binding and uptake of diphtheria toxin by toxin-resistant Chinese hamster ovary and mouse cells. (kiev.ua)
  • 14. Labyntsev A. I., Korotkevich N. V., Kaberniuk A. A., Romaniuk S. I., Kolybo D. V., Komisarenko S. V. Interaction of diphtheria toxin B subunit with sensitive and insensitive mammalian cells. (kiev.ua)
  • 15. Kaberniuk A. A., Labyntsev A. I., Kolybo D. V., Oliinyk O. S., Redchuk T. A., Korotkevych N. V., Gorchev V. F., Karakhim S. O., Komisarenko S. V. Fluorescent derivatives of diphtheria toxin subunit B and their interaction with Vero cells. (kiev.ua)
  • 16. Labyntsev A. J., Korotkevych N. V., Manoilov K. J., Kaberniuk A. A., Kolybo D. V., Komisarenko S. V. Recombinant fluorescent models for studying the diphtheria toxin. (kiev.ua)
  • For each country, a nationally representative population sample was collected across the entire age range and was tested for antibodies to diphtheria toxin. (cambridge.org)
  • Tetanus toxoid is manufactured by first culturing Clostridium tetani and then detoxifying the toxin with formaldehyde. (medscape.com)
Antigens1
Immunogenicity1
  • In conclusion, BR-TD-1001 was safe, well-tolerated, and showed sufficient immunogenicity as a booster for diphtheria and tetanus. (druglib.com)
Hepatitis B Surface Antigen1
  • Comvac 5 ® is a uniform suspension of Diphtheria toxoid, Tetanus toxoid, B pertussis whole cell inactivated, Hepatitis B Surface Antigen and Hib PRP adsorbed on a mineral carrier Aluminium phosphate gel in isotonic saline solution (in-situ gel formulation).The Diphtheria and Tetanus components are toxoids prepared by formalin inactivation using established technology. (bharatbiotech.com)
Antibody4
  • The geometric mean titer of anti-diphtheria antibody in the test group was significantly higher than the value of the placebo (P = 0.0347) while it was not for the value of the active comparator (P = 0.8484). (druglib.com)
  • Title : Antibody response to booster dose of diphtheria and tetanus toxoids Personal Author(s) : Volk, V. K.;Gottshall, R. Y.;Anderson, H. D.;Top, Franklin H.;Bunney, W. E.;Gilbert, Maud G. (cdc.gov)
  • The Third National Health and Nutrition Examination Survey (NHANES III), 1988-94, Series 11, No. 16A (Diphtheria Antibody Data and Documentation) Data Release. (cdc.gov)
  • This data release, Series 11 No. 16A, contains the NHANES III Diphtheria Antibody data file and documentation. (cdc.gov)
Outbreaks3
  • Outbreaks of diphtheria are rare in the United States but are still widespread in less developed nations. (familyeducation.com)
  • There is presently a resurgence of diphtheria outbreaks in Nigeria. (who.int)
  • The Nigeria Center for Disease Control (NCDC) was notified of suspected diphtheria outbreaks in Lagos and Kano States, Nigeria, in December 2022 and has been issuing monthly reports since that time. (who.int)
Serum2
  • Zur Behandlung diphtheriekranker Menschen mit Diphtherieheilserum [On the treatment of diphtheria patients with curative diphtheria serum]. (jameslindlibrary.org)
  • This toxoid commonly is combined with diphtheria toxoid, and both serve to induce production of serum antibodies to toxins produced by the bacteria. (medscape.com)
Immunity1
Anaphylaxis1
  • Do not administer VAXNEUVANCE to individuals with a severe allergic reaction (e.g., anaphylaxis) to any component of VAXNEUVANCE or to diphtheria toxoid. (merck.com)
Vaccinations1
  • Safety of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis and influenza vaccinations in pregnancy. (cdc.gov)
Adults1
Commonly1
  • Diphtheria is an infectious and communicable disease most commonly spread through bacteria from respiratory droplets from coughing or sneezing. (familyeducation.com)
Search1
  • Results of search for 'su:{Tetanus toxoid. (who.int)
Acellular pertussis17
Vaccines10
Induce at least 2 units2
  • Each 0.5 mL dose is formulated to contain 6.7 Lf of diphtheria toxoid and 5 Lf of tetanus toxoid (both toxoids induce at least 2 units of antitoxin per mL in the guinea pig potency test), and 46.8 m g of pertussis antigens. (rxlist.com)
  • The tetanus and diphtheria toxoids induce at least 2 units and 1 unit of antitoxin per mL of serum, respectively, in the guinea pig potency test. (nih.gov)
Conjugate vaccine1
  • Post marketing safety evaluations of quadrivalent meningococcal diphtheria-toxoid conjugate vaccine (MenACWY-D) have focused on post-vaccination risk of Guillain Barré syndrome (GBS), adverse events (AEs) after maternal vaccination, and comparative studies with the newer quadrivalent meningococcal CRM 197 conjugate vaccine (MenACWY-CRM). (nih.gov)
Poliovirus vaccine1
  • Do not administer VAXELIS to anyone with a history of severe allergic reaction to a previous dose of VAXELIS, any ingredient of VAXELIS, or any other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or Hib vaccine. (vaxelistransition.com)
Doses5
  • Most controls (92%) had received three or more doses of a diphtheria toxoid vaccine, compared with 72% of case-patients. (nih.gov)
  • To control and prevent diphtheria epidemics, it is necessary to achieve and maintain high vaccination coverage with three or more doses of diphtheria toxoid among adults and children. (nih.gov)
  • How many doses of diphtheria toxoid are required for protection in adults? (nih.gov)
  • If the person is pregnant, they are recommended to receive 3 doses of diphtheria-toxoid vaccine at 0, 4 weeks and 6-12 months. (health.gov.au)
  • Booster doses of TDVAX at doses of 1 Lf and 5 Lf of tetanus toxoid induced tetanus antitoxin levels greater than 0.01 units/mL when administered to all 36 adults who had received prior tetanus immunizations. (nih.gov)
Immunisation2
  • Active immunisation reduces the number of clinical case of diphtheria without drastically affecting the carrier state. (pediatriconcall.com)
  • 18 An interesting case-control study of Harrison et al suggested that the frequency of prior immunisation (tetanus toxoid, influenza, and others) was higher among patients with inflammatory polyarthritis, including RA, than among age and sex matched controls. (bmj.com)
Status against diphtheria1
Pertussis antigens1
Poliomyelitis2
  • Pediarix is a vaccine used for the prevention of diphtheria, tetanus (lockjaw), pertussis (whooping cough), infection caused by all known subtypes of hepatitis B virus, and polio (poliomyelitis). (rxwiki.com)
  • Hexaxim helps to protect against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and serious diseases caused by Haemophilus influenzae type b. (mydr.com.au)
Diseases1
  • Vaccine preventable diseases surveillance programme revealed that 533 microbiologically proven diphtheria cases were diagnosed in Kerala in the year 2016. (pediatriconcall.com)
Adolescents and adults1
Standardization1
  • Preparation and Dosage" (1931, with Minnie Eisner and Erla Jackson) "Predominant Strain of B. influenzae in Influenzal Meningitis" (1933) "Effectiveness of Standard Diphtheria Antitoxin Against all Types of Diphtheria Infection" (1933, with Minnie Eisner and Erla Jackson) "The Effect of Temperature on the Antigenic Value of Diphtheria Toxoid" (1935, with Minnie Eisner) "Standardization and Application of Different Preparations of Diphtheria Toxoid" (1936) Povitzky became a United States citizen in 1904. (wikipedia.org)
Whooping cough2
Vaccination coverage1
Preparation1
Toxins1
  • Tetanus and diphtheria toxins produced during growth of the cultures are detoxified with formaldehyde. (nih.gov)
Infection2
  • This review aims to revisit the diphtheria infection and analyse the factors behind the resurgence of the it in recent years. (pediatriconcall.com)
  • 3) Transmission of C. diphtheria occurs more commonly through droplet infection and less commonly through skin lesions and fomites. (pediatriconcall.com)
Vaxelis1
  • If Guillain-Barré syndrome occurred within 6 weeks of receipt of a prior vaccine containing tetanus toxoid, the risk for Guillain-Barré syndrome may be increased following VAXELIS. (vaxelistransition.com)
Bacteria4
Decreases1
  • Although there have been no decreases in production of tetanus toxoid (TT), availability is low because of increased use during the Td shortage. (cdc.gov)
Lead to difficulty1
  • Diphtheria can lead to difficulty in swallowing, breathlessness, heart failure and paralysis. (hse.ie)
Hypersensitivity reaction1
  • Persons who experienced an Arthus-type hypersensitivity reaction following a prior dose of a tetanus toxoid-containing vaccine should not receive BOOSTRIX unless at least 10 years have elapsed since the last dose of a tetanus toxoid-containing vaccine. (nih.gov)
Booster1
Infectious1
  • Diphtheria is an infectious disease that usually first affects the throat. (mydr.com.au)
Prevent3
20231
  • It is very important to immunise against diphtheria as there have been cases of diphtheria reported in the UK and Belgium in 2023. (hse.ie)
TDVAX2
  • Each 0.5 mL dose of MassBiologics' TDVAX is formulated to contain the following active ingredients: 2 Lf of tetanus toxoid and 2 Lf of diphtheria toxoid. (nih.gov)
  • A severe allergic reaction (e.g., anaphylaxis) occurring after a previous dose of this vaccine, or any other tetanus or diphtheria toxoid-containing vaccine, or any component of this vaccine is a contraindication to administration of MassBiologics' TDVAX vaccine. (nih.gov)
Severe1
  • Severe allergic reaction (e.g., anaphylaxis) after a previous dose of any tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine or to any component of BOOSTRIX. (nih.gov)
Additional dose1
  • One additional dose of a diphtheria- and tetanus- (dT) containing vaccine can be administered one month later followed by a 3rd dose of a diphtheria or dT containing vaccine 6 months after the first dose to optimize protection against disease (see section 5.1). (medicines.org.uk)
Effectiveness2
  • Prior to the completion of this and other studies, low effectiveness of diphtheria toxoid-containing vaccine was suspected to be a major contributing factor to the diphtheria epidemic that began in the Russian Federation in 1990. (nih.gov)
  • Low vaccine effectiveness was not a contributing factor to the diphtheria epidemic in the Russian Federation. (nih.gov)
Aluminum2